REMAB Therapeutics

REMAB Therapeutics

Green light to REMAB, a new IDIBELL Spin-Off | IDIBELL.

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR2018201920202021
Revenues<1m<1m<1m<1m
% growth-198 %227 %17 %
EBITDA-<1m<1m<1m
% EBITDA margin-7 %7 %9 %
Profit---(<1m)
  • Edit
DateInvestorsAmountRound

N/A

Spinout
Total Funding-

Recent News about REMAB Therapeutics

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.